We keep the patient at the centre of everything we do.
From the research, drug development and healthcare environment, through to issues affecting the delivery of care to patients at the hospital bedside, policy impacts on myeloma patients and their families at every point in their myeloma journey.
We work with patients and their families, government, pharmaceutical industry, researchers and healthcare professionals to influence decision-making and policy to the benefit of the myeloma community.
Currently we are focused on following key policy areas:
- The myeloma research environment
- The regulation of medicines
- The pricing of medicines
- Access to treatment
- NHS reforms and commissioning